ProCE Banner Activity

Targeted Therapy Beyond EGFR, ALK, and ROS1: A New Frontier in NSCLC Care

Clinical Thought
Thomas Stinchcombe, MD, discusses rare driver mutations that will soon affect testing and treatment decisions for patients with advanced NSCLC.

Released: May 10, 2017

Expiration: May 09, 2018

No longer available for credit.

Share

Faculty

Thomas Stinchcombe

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Thomas Stinchcombe, MD, has disclosed that he has received consulting fees from Regeneron.